Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub

This article was originally published in PharmAsia News

Executive Summary

Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.

You may also be interested in...

Korea FDA Prepares Guidelines On Phase 0 Clinical Trials To Draw More Early-stage Trials

SEOUL - Korea FDA is gearing up to release guidelines on Phase 0 clinical trials in the first half of next year under its broader ambition to draw more early-stage clinical trials to the country

Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says

SINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore

South Korea Beefs Up Infrastructure To Lead Asia In Early-Stage Clinical Trials

SEOUL - South Korea is drawing more Phase I and Phase II clinical trials from its former foothold in Phase III and post-approval trials, Korea National Enterprise for Clinical Trials reported


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts